We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychi... Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. Show more
Trial did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024 Future...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its...
Phase 3 RAISE trial interim analysis enrollment target achieved with Data Monitoring Committee (DMC) review scheduled and topline results expected in first half of Q2 2024 Phase 3 TrustTSC trial...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -6.745 | -82.0559610706 | 8.22 | 8.26 | 1.11 | 11133016 | 1.46634065 | CS |
4 | -7.795 | -84.0884573894 | 9.27 | 9.41 | 1.11 | 3325417 | 2.32072652 | CS |
12 | -8.525 | -85.25 | 10 | 10.5 | 1.11 | 1365324 | 3.77430298 | CS |
26 | -5.305 | -78.2448377581 | 6.78 | 11.26 | 1.11 | 868155 | 5.01064485 | CS |
52 | -6.015 | -80.3070761015 | 7.49 | 11.26 | 1.11 | 827830 | 6.68881399 | CS |
156 | -12.475 | -89.4265232975 | 13.95 | 19.83 | 1.11 | 482567 | 7.36876715 | CS |
260 | -2.665 | -64.3719806763 | 4.14 | 20.04 | 0.77 | 1005635 | 4.58836827 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions